Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking forward for things coming together here even with the unfortunate delay the company is having to deal with due to the Covid. Hopefully their last postponement is now coming to an end!
I anticipate this thing waking up in a big way!
Innovest Global Provides Update on Acquisition Plans
https://www.google.com/amp/s/www.accesswire.com/users/amp/viewarticle.aspx%3fid=589277
"signed Letters of Intent to acquire three businesses, and is pursuing a fourth acquisition target. If closed, these acquisitions would position Innovest to achieve more gross profit than ever before, while SEC registration and uplist to the OTCQB market are simultaneously pursued."
At least they're paying to get more eyes on the stock.
https://spotlightgrowth.com/index.php/2020/04/06/innovest-global-inc-ivst-an-emerging-diamond-in-the-rough/
When?
I enjoy history. I threw money at this awhile back and basically did a set and forget it the strategy, lol, so for me, it is what it is or what it becomes.
Ready and waiting!
Appreciate the PM Hen. Keep yourself and the family safe during these times.
Gilead just jumped after hours on their positive results. Many companies jockeying for position to find the best working treatment.
I bought shares. I don't expect any tremendous moves, just looking to hold for the long run. Looks like this company has a ton of outstanding shares so I assume slower moves. In a positive note, it looks like they have had a couple of forward splits as they've grown over the years. You can find good info about the company at the OTC Markets website.
The study is moving quickly. Check out those dates.
https://clinicaltrials.gov/ct2/show/NCT04346355
Some info for you.
https://www.cancernetwork.com/news/fda-approves-phase-iii-clinical-trial-tocilizumab-covid-19-pneumonia
(Genentech, the agent’s developer.)
Yes, to answer your question.
https://en.m.wikipedia.org/wiki/Genentech
I'll be here waiting!
As part of Innovest Global's business strategy to remain a pure play industrials company, StemVax will thrive as a stand-alone public company once spun out from Innovest Global in mid-2020. By controlling the intellectual property and spinout, Innovest is expected to own a significant stake in the common stock of this forthcoming company. This investment in StemVax is expected to significantly contribute to the strength of Innovest's balance sheet, providing the company the opportunity to generate cash without shareholder dilution and/or pay shares as dividends directly to Innovest shareholders in the future.
https://www.streetinsider.com/dr/news.php?id=16562072
They no longer have this product.
The Company commercially launched its iodine breast health supplement, VI2OLET, in December 2014. In November 2018, the Company divested the rights to develop, manufacture, market and sell its molecular iodine technology, including VI2OLET. This divestiture resulted in a de minimis loss in the fourth quarter of fiscal year 2019, which is included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. All tangible and intangible assets related to VI2OLET, including but not limited to existing customer and vendor arrangements, were included in this divestiture.
Upper Street Marketing Enters into Agreement for Processing its Hemp Biomass – Approximately $13.2 Million of Revenues Projected
San Diego, CA, February 19, 2020 -- Upper Street Marketing Inc. (OTC Markets: symbolUPPR) and its wholly owned subsidiary Growing Springs Holding Corp. have entered into an agreement to sell approximately 1.2 million pounds of CBD based hemp biomass to Victory Americas Group, LLC (Victory) who will in turn process the hemp biomass into T-Free CBD Distillate and pay UPPR from the sale of the distillate.
UPPR will receive approximately $13,200,000 from the sale of the distillate from Victory.
Victory expects to start processing the biomass within the next three weeks and to complete the processing within 30 days from starting.
This agreement forms part of the asset sale from Upper Street previously disclosed in our news release dated February 12, 2020.
This deal will provide UPPR with significant revenues and cash to advance UPPRs business, Joseph Earle, UPPR CEO explains.
https://www.otcmarkets.com/stock/UPPR/news/Upper-Street-Marketing-Enters-into-Agreement-for-Processing-its-Hemp-Biomass--Approximately-132-Million-of-Revenues-Proj?id=254408
Innovest Global to Present at the LD Micro Virtual Investor Conference on March 4, 2020 at 3:40 p.m. ET
Management to Showcase New Investor Presentation & Business Model During Online Event
CLEVELAND, OH / ACCESSWIRE / February 25, 2020 / Innovest Global, Inc. (OTC:IVST), a diversified industrials company, will participate at the LD Micro Virtual Investor Conference on March 4, 2020 at 3:40 p.m. Eastern time.
Innovest Global management will present an overview of the business model and key growth initiatives. The webinar will be accompanied by a presentation and followed by a question and answer session, which can be accessed via the webcast link below.
To access the webinar, please use the following information:
LD Micro Virtual
Date: Wednesday, March 4, 2020
Time: 3:40 p.m. Eastern time (12:40 p.m. Pacific time)
Webcast: https://www.webcaster4.com/Webcast/Page/2019/33380
The conference will be held via webcast and will feature over 40 companies in the small and micro-cap space. View Innovest Global's profile here.
Please register for the LD Micro Webinar 5-10 minutes prior to the start time. If you have any difficulty connecting to the webinar, please contact MZ Group at 1-949-491-8235. The webinar will be broadcast live and available for replay via the investor relations section of the Company's website
They had to. "Schedule 13G is due within 45 calendar days after the calendar year".
https://www.investopedia.com/terms/s/schedule13g.asp
Patiently waiting myself.
They're alive! Let's get this thing going!
Actually no name change. I was referring to NYSE American, formerly known as the American Stock Exchange (AMEX).
Biopharmx has always been under this exchange and with the .20/30 day rule.
Requirement here is .20 for 30 days.
They addressed that in the past as shown in this link.
https://mobile.twitter.com/biopharmx/status/978709747896479744?lang=en
That sounds great. Appreciate you reaching out and sharing. I haven't been adding due to the silence. You info here now has me thinking. Thanks!
"Stay tuned for big updates coming soon!"
Good, cause these crickets are getting to me.
In regards to that last message, it did just break the 200MA so proceed with caution.
No prob. Speaking about Foamix though, it's looking ready to possibly bounce off lower support from August. Possibly tomorrow. Might be a little money to be made there if it doesn't break support.
Happy holidays to you!
Hey, good to hear from you! Still sitting here on hope. My thoughts, they're working to make a deal. In a very tough position. I believe if a deal can be made, it would be good for a nice little jump for the low averaged, but I believe longs still have a ways to go because the deal would still put us longs through P3 and so on, you know. More waiting as those trials happen. Sure, they could merge and we get shares from the merged company, and wait and see what they can do with the BPX-(01)(04) product.
Did you follow Foamix's deal? Not too exciting there, so my hopes are low.
So, possibly good for a flip if a deal is made but a long road for the high average longs. Just my opinion... Nothing good has ever come from this ticker yet, so go ahead BPMX, surprise me!
Whatever happened to the hemp harvest this year?
Elkonig, I sold my entire position just before this whole debacle. I'm just sticking around because there was "supposed" promise in this company and I'm willing to jump back in if these guys can get things straightened out. Although, the silence, deep past harvest, doesn't look good.
IVST on Twitter
"Thanks for your support! As we have approached some of the milestones we’ve been pursuing, management decided our recent updates should be less frequent and more meaningful. We’re more excited than ever with A LOT going on! Reach us any time at 440.644.1027 or via email for more!"
6:39 AM · Nov 1, 2019
https://iborrowdesk.com/report/DCGD
Oops, repeated
Appreciate your input. Yep, I'm holding and waiting.
I was wondering about the harvest. I was thinking we should be hearing something soon. Keeping watch!
Still watching for an update here as well.
https://www.sec.gov/litigation/apdocuments/ap-3-19250.xml
Right! Looks like the paid pumpers have left the building. I asked awhile back why the company slowed down the tweets and if they were in a quiet period. Thankfully I only threw a couple grand at this one and have been able to cover losses over at DCGD swing plays. At this point I'm letting the cash sit here for hopefully a future jump! I mean, why are they all of a sudden so quiet? They recently received that new 200k facility. What's going on in the old Walmart? This had been dropping too long now, and we're do for a pop dang it!
Apparently their still alive! Innovest tweeted Oct 8th, "OTC Markets | IVST expands board of directors and management changes! Very exciting #news as IVST pursues uplist and progress with rapidly growing industrial business. Biotech spinout coming soon!"
Maybe this site, https://iborrowdesk.com/
It took me 3 months of collecting cans and bottles to buy into this stock, and this is thanks I get?! Hey mods! What's going on here? Anything? I have another round of cans and bottles if I can find an open recycle center these days...
Is this company going through a quiet period or something? They used to tweet weekly and now they're just silent. Any updates?
That's it for me. Starting to look like a downtrend is set into motion.
BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American
SAN JOSE, Calif., Sept. 20, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, received a notice on September 19, 2019 from the NYSE American LLC (the "NYSE American") granting the Company an extension until March 24, 2020 to regain compliance with certain NYSE American continued listing standards related to its stockholders' equity balance.
On September 24, 2018, the Company received a deficiency letter from NYSE American stating that the Company was not in compliance with the continued listing standards as set forth in Section 1003(a)(i)-(iii) of the NYSE American Company Guide, which requires listed companies to maintain stockholders' equity of $6.0 million or more if they have reported losses from continued operations and/or net losses in their five most recent fiscal years (Section 1003(a)(iii)). Following a review of the Company's request for extension and accompanied compliance plan, the NYSE American has granted a six-month extension predicated on it regaining compliance with this listing requirement by the end of the compliance period.
"We appreciate the continued cooperation from the NYSE American," said Dr. Tierney, BioPharmX CEO. "In working closely with the Locust Walk team, our goal is to announce a strategic partnership transaction to advance our late-stage topical minocycline drug candidates in Q4 2019, which should contribute to regaining compliance."
The Company's common stock will continue to be listed and traded on NYSE American during the extended cure period, subject to the Company's compliance with NYSE American's other applicable continued listing standards. The letter does not affect the Company's business operations or its Securities and Exchange Commission reporting requirements.
From the start of Monday, I'll be riding this thing back up to triple digits!